Tirzepatide
Dual incretin (GIP) receptor agonist studied in vitro.
Specification
- Catalogue ID: SP148
- Listed purity specification: 99.8%
- Formulation: Lyophilized
- Quantity: 30mg / Vial
- Price: £228.00
Dual GIP/GLP-1 receptor · incretin pharmacology research
Tirzepatide is a 39-amino-acid synthetic dual agonist peptide with activity at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Vivera supplies it strictly as a research reagent.
In receptor-binding assays and cell-based functional studies, tirzepatide engages GIPR and GLP-1R through Gαs-coupled adenylyl cyclase activation. Its pharmacology at each receptor has been characterised in recombinant receptor systems and primary cell lines derived from pancreatic and metabolic tissues.
No physiological or therapeutic properties are claimed; supplied strictly as a research reagent for in-vitro laboratory use only. Not for human or clinical use.
Compound identity
- CAS number: 2023788-19-2
- Molecular formula: C₂₂₅H₃₄₈N₄₈O₆₈S
- Molecular weight: 4813.48 Da
- Solubility: Soluble in water; stable in aqueous solution at physiological pH
- Reconstitution: Reconstitute lyophilised powder in bacteriostatic water; consult vial label for specific volume
For in-vitro laboratory research use only. Not for human or veterinary use, consumption, or therapeutic application. No medical claims are made.